CLINICAL_TRIALS
trial_result
· 2025-12-23
Clinical Trial Update: Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) [Phase 2]
Summary
Phase 2 study of MGL-3196 (resmetirom) in non-alcoholic steatohepatitis has completed, with results posted on 2025-12-23.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Madrigal Pharmaceuticals, Inc. | Conditions: Non-alcoholic Steatohepatitis | Phase 2 | Status: COMPLETED | Results posted: 2025-12-23